Discover how understanding your viral load and CD4 count puts you in control of HIV treatment and transforms confusing ...

Learn what a negative HIV test means, why the window period matters, and when you should consider retesting. Essential health ...

Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The recent news of Gilead Sciences' groundbreaking new HIV preventative drug, Lenacapavir, offers a beacon of hope in the ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

LA CAB plus RPV effectively maintained virologic suppression among patients with infection in real-world clinical practice.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...